Here's the PR on Kevetrin/sunitinib against renal

Here's the PR on Kevetrin/sunitinib against renal cancer. Sunitinib is Pfizer's multikinase inhibitor.

"Research by BIDMC combined Kevetrin™ with sunitinib on cell line 786, a drug-resistant renal cancer. Cellceutix was advised by the researchers that “the Kevetrin/sunitinib combination is the first we’ve used in which actual tumor shrinkage is noted.”

http://cellceutix.com/cellceutix-reports-in-v...k2XMA.dpbs

Here's the latest status from the corporate update.

"Kevetrin- Renal Cancers

We have also discussed plans for Kevetrin to be independently studied by investigators at Beth Israel Deaconess Medical Center (BIDMC) in combination with a tyrosine kinase inhibitor as a potential new combination therapy for renal cancer, a tumor that is particularly resistant to therapy. In its research, BIDMC has noted in vivo tumor regression in a drug-resistant renal cancer cell line exposed to the combination of Kevetrin and sunitinib. We have previously supplied BIDMC requested information to investigate a Specialized Programs of Research Excellence (SPORE) grant. It is hopeful these plans will progress to the initiation of a multicenter Phase 2 clinical study of Kevetrin in combination with a tyrosine kinase inhibitor."

http://cellceutix.com/cellceutix-provides-cor...w3ytz.dpuf

Quote:

---

Seems I remember a release two years ago that the company lent Pfizer some of their KEVETRIN for some inhouse trial combined with one of their own development drugs.

---

I think BIDMC will get the SPORE grant next year and this combination trial will be the third Phase 2 trial for Kevetrin.